

AndrÃ© J Scheen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2271508/publications.pdf>

Version: 2024-02-01

342
papers

28,222
citations

8172

76
h-index

5986

160
g-index

391
all docs

391
docs citations

391
times ranked

25325
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Review of Endocrinology and Metabolism, 2022, 17, 35-46. | 1.2 | 8 |
| 2 | Association Between the <i>ACE</i> Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. Diabetes Care, 2022, 45, 407-415. | 4.3 | 3 |
| 3 | Choix entre une gliptine et une gliflozine chez le patient âgé avec un diabète de type 2. Medecine Des Maladies Metaboliques, 2022, , . | 0.1 | 0 |
| 4 | Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers. Diabetes and Metabolism, 2022, 48, 101315. | 1.4 | 10 |
| 5 | Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies. Diabetes Epidemiology and Management, 2022, 6, 100054. | 0.4 | 7 |
| 6 | Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?. Diabetes and Metabolism, 2022, 48, 101325. | 1.4 | 18 |
| 7 | When therapeutic drugs lead to diabetes. Diabetologia, 2022, 65, 751-762. | 2.9 | 12 |
| 8 | Add-on value of tirzepatide versus semaglutide. Lancet Diabetes and Endocrinology, the, 2022, 10, 377-378. | 5.5 | 6 |
| 9 | Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?. Diabetes and Metabolism, 2021, 47, 101209. | 1.4 | 5 |
| 10 | Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. JAMA Cardiology, 2021, 6, 139. | 3.0 | 50 |
| 11 | Existe-t-il encore une place pour les sulfamides hypoglycémisants dans le traitement du diabète de type 2 en 2021?. Medecine Des Maladies Metaboliques, 2021, 15, 45-52. | 0.1 | 0 |
| 12 | DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabetes and Metabolism, 2021, 47, 101213. | 1.4 | 32 |
| 13 | Exciting breakthroughs in the management of diabetes mellitus. Diabetes Epidemiology and Management, 2021, 1, 100005. | 0.4 | 3 |
| 14 | Médicaments et prise de poids. , 2021, , 91-95. | | 0 |
| 15 | Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opinion on Pharmacotherapy, 2021, 22, 2149-2165. | 0.9 | 18 |
| 16 | <i>ACE</i> I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. Diabetes Care, 2021, 44, 1377-1384. | 4.3 | 6 |
| 17 | Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. CKJ: Clinical Kidney Journal, 2021, 14, 2463-2471. | 1.4 | 12 |
| 18 | L'épopée des insulines des années 1930 aux années 1980. Medecine Des Maladies Metaboliques, 2021, 15, 3S25-3S31. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | La dysfonction endothéliale: signification clinique et implications thérapeutiques. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 496-504. | 0.1 | 0 |
| 20 | GLP-1 receptor agonists: which added value when increasing the dose?. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 546-548. | 5.5 | 5 |
| 21 | The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. <i>Diabetes and Metabolism</i> , 2021, 47, 101285. | 1.4 | 18 |
| 22 | Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. <i>Diabetes and Metabolism</i> , 2021, 47, 101220. | 1.4 | 38 |
| 23 | Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2021, 47, 101275. | 1.4 | 12 |
| 24 | Sulphonylureas in the management of type 2 diabetes: To be or not to be?. <i>Diabetes Epidemiology and Management</i> , 2021, 1, 100002. | 0.4 | 5 |
| 25 | Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies. <i>Diabetes Epidemiology and Management</i> , 2021, 3, 100021. | 0.4 | 5 |
| 26 | Series: Implications of the recent CVOTs in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 159, 107726. | 1.1 | 15 |
| 27 | Challenging 2019 ESC guidelines for the management of type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 181-185. | 1.4 | 16 |
| 28 | Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study. <i>Diabetes Therapy</i> , 2020, 11, 1835-1847. | 1.2 | 6 |
| 29 | Glucotoxicité et lipotoxicité dans le diabète de type 2: comment protéger la cellule β ? <i>Medecine Des Maladies Metaboliques</i> , 2020, 14, 549-557. | 0.1 | 0 |
| 30 | Metformin and COVID-19: From cellular mechanisms to reduced mortality. <i>Diabetes and Metabolism</i> , 2020, 46, 423-426. | 1.4 | 139 |
| 31 | Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 350-352. | 5.5 | 5 |
| 32 | Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 556-577. | 4.3 | 169 |
| 33 | SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2765-2779. | 1.1 | 26 |
| 34 | SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?. <i>Diabetes and Metabolism</i> , 2020, 46, 343-344. | 1.4 | 17 |
| 35 | Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , 2020, 59, 981-994. | 1.6 | 13 |
| 36 | Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 243-256. | 1.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions. <i>Obesity Facts</i> , 2020, 13, 1-28. | 1.6 | 15 |
| 38 | Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. <i>Diabetes and Metabolism</i> , 2020, 46, 186-196. | 1.4 | 27 |
| 39 | Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. <i>Diabetes and Metabolism</i> , 2020, 46, 265-271. | 1.4 | 119 |
| 40 | Proposition de l'expérience belge avec les inhibiteurs des SGLT2. <i>Medecine Des Maladies Metaboliques</i> , 2020, 14, 320-330. | 0.1 | 3 |
| 41 | Études cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, S10-S24. | 0.1 | 6 |
| 42 | SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 818-820. | 5.5 | 7 |
| 43 | Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. <i>Current Cardiology Reports</i> , 2019, 21, 70. | 1.3 | 88 |
| 44 | Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new "French paradox". <i>Diabetes and Metabolism</i> , 2019, 45, 319-321. | 1.4 | 8 |
| 45 | Prise de position de la Société Francophone du Diabète (SFD) : Évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, 195-209. | 0.1 | 7 |
| 46 | An update on the safety of SGLT2 inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 295-311. | 1.0 | 122 |
| 47 | Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. <i>Diabetes and Metabolism</i> , 2019, 45, 213-223. | 1.4 | 99 |
| 48 | Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2 en 2019. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, 711-732. | 1.1 | 19 |
| 49 | Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919. | 1.0 | 32 |
| 50 | Preventing and treating kidney disease in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 277-294. | 0.9 | 31 |
| 51 | Type 2 diabetes mellitus and osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 9-19. | 1.6 | 110 |
| 52 | Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?. <i>Diabetes Research and Clinical Practice</i> , 2019, 147, 169-171. | 1.1 | 9 |
| 53 | Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 110-121. | 1.4 | 42 |
| 54 | Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management and potentially beyond. <i>Annals of Translational Medicine</i> , 2019, 7, S132-S132. | 0.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Effets des traitements anti-hyperglycémisants sur les complications cardiovasculaires et rénales du patient diabétique de type 2 : leçons des grands essais d'intervention. , 2019, , 283-295. | | 0 |
| 56 | Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. <i>Medicine Des Maladies Metaboliques</i> , 2018, 12, 22-30. | 0.1 | 9 |
| 57 | The safety of gliptins : updated data in 2018. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 387-405. | 1.0 | 101 |
| 58 | Does lower limb amputation concern all SGLT2 inhibitors?. <i>Nature Reviews Endocrinology</i> , 2018, 14, 326-328. | 4.3 | 42 |
| 59 | Type 2 Diabetes and Thiazide Diuretics. <i>Current Diabetes Reports</i> , 2018, 18, 6. | 1.7 | 23 |
| 60 | GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. <i>Diabetes and Metabolism</i> , 2018, 44, 193-196. | 1.4 | 25 |
| 61 | Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018, 41, 596-603. | 4.3 | 59 |
| 62 | New hope for glucokinase activators in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 591-593. | 5.5 | 14 |
| 63 | Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 620-628. | 2.2 | 121 |
| 64 | Metformin â€” a cardiovascular moderator of DPP4 inhibitors?. <i>Nature Reviews Endocrinology</i> , 2018, 14, 8-9. | 4.3 | 9 |
| 65 | Renal outcomes with dipeptidyl peptidase-4 inhibitors. <i>Diabetes and Metabolism</i> , 2018, 44, 101-111. | 1.4 | 19 |
| 66 | Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?. <i>Annals of Translational Medicine</i> , 2018, 6, S68-S68. | 0.7 | 8 |
| 67 | Do Positive Cardiovascular Outcomes Trials With New Glucose-Lowering Agents Overestimate Both Efficacy and Safety?. <i>Circulation Research</i> , 2018, 123, e3-e4. | 2.0 | 0 |
| 68 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 1519-1529. | 6.3 | 1,179 |
| 69 | Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. <i>Diabetes and Metabolism</i> , 2018, 44, 457-464. | 1.4 | 210 |
| 70 | Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018, 41, 2552-2559. | 4.3 | 177 |
| 71 | Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 88-100. | 1.1 | 51 |
| 72 | The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 837-848. | 1.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Cardiovascular Effects of New Oral Glucose-Lowering Agents. <i>Circulation Research</i> , 2018, 122, 1439-1459. | 2.0 | 220 |
| 74 | Weight loss expectations and determinants in a large community-based sample. <i>Preventive Medicine Reports</i> , 2018, 12, 12-19. | 0.8 | 9 |
| 75 | Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort. <i>Diabetes and Metabolism</i> , 2018, 44, 465-472. | 1.4 | 27 |
| 76 | Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. <i>Diabetes and Metabolism</i> , 2018, 44, 386-392. | 1.4 | 25 |
| 77 | Relations entre gain barorÄ©flexe et autres marqueurs de risque chez le patient diabÄ©tique de type 2. <i>Annales De Cardiologie Et D'Angiologie</i> , 2017, 66, 1-6. | 0.3 | 2 |
| 78 | Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. <i>Diabetes and Metabolism</i> , 2017, 43, 99-109. | 1.4 | 41 |
| 79 | Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 236-238. | 5.5 | 14 |
| 80 | Pharmacotherapy of "treatment resistant" type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 503-515. | 0.9 | 29 |
| 81 | 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet</i> , 2017, 389, 1399-1409. | 6.3 | 502 |
| 82 | SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease. <i>Evidence-Based Medicine</i> , 2017, 22, 69-70. | 0.6 | 2 |
| 83 | Dulaglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 485-496. | 1.4 | 30 |
| 84 | GLP-1 receptor agonists and heart failure in diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 2S13-2S19. | 1.4 | 56 |
| 85 | Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 299-313. | 1.4 | 28 |
| 86 | "Treatment-resistant" type 2 diabetes: Which definition for clinical practice?. <i>Diabetes and Metabolism</i> , 2017, 43, 295-297. | 1.4 | 4 |
| 87 | Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 224-237. | 1.1 | 15 |
| 88 | Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 583-592. | 1.5 | 8 |
| 89 | Possible survivorship bias rather than reverse causality in EMPA-REG OUTCOME. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 290. | 1.1 | 3 |
| 90 | Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 703-718. | 1.6 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Understanding and overcoming metformin gastrointestinal intolerance. Diabetes, Obesity and Metabolism, 2017, 19, 473-481. | 2.2 | 141 |
| 92 | Factors associated with reaching or not reaching target HbA1c after initiation of basal or premixed insulin in patients with type 2 diabetes. Diabetes and Metabolism, 2017, 43, 69-78. | 1.4 | 8 |
| 93 | Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. Medecine Des Maladies Metaboliques, 2017, 11, 577-593. ^{0.1} | | 48 |
| 94 | Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology, 2017, 10, 1303-1316. | 1.3 | 6 |
| 95 | Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert Opinion on Investigational Drugs, 2017, 26, 1373-1389. | 1.9 | 80 |
| 96 | Canagliflozin: A Review in Type 2 Diabetes. Drugs, 2017, 77, 1577-1592. | 4.9 | 32 |
| 97 | Pharmacological management of type 2 diabetes: what's new in 2017?. Expert Review of Clinical Pharmacology, 2017, 10, 1383-1394. | 1.3 | 19 |
| 98 | Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology, 2017, 5, 864-876. | 5.5 | 244 |
| 99 | Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies. Clinical Pharmacokinetics, 2017, 56, 193-205. | 1.6 | 25 |
| 100 | Hypoglycemic State, Nondiabetic. , 2017, , 270-274. | | 0 |
| 101 | Protection cardiovasculaire par les inhibiteurs des SGLT2 (gliflozines) : l'EMPA-REG OUTCOME et le CANVAS. Revue Medicale Suisse, 2017, 13, 1421-1426. | 0.0 | 3 |
| 102 | Body image discrepancy and subjective norm as mediators and moderators of the relationship between body mass index and quality of life. Patient Preference and Adherence, 2016, Volume 10, 2261-2270. | 0.8 | 8 |
| 103 | Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de type 2. Medecine Des Maladies Metaboliques, 2016, 10, 725-731. | 0.1 | 0 |
| 104 | Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis. Drug Metabolism and Disposition, 2016, 44, 792-799. | 1.7 | 36 |
| 105 | Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 200-205. | 1.4 | 30 |
| 106 | Precision medicine: The future in diabetes care?. Diabetes Research and Clinical Practice, 2016, 117, 12-21. | 1.1 | 40 |
| 107 | Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Research and Clinical Practice, 2016, 121, 204-214. | 1.1 | 40 |
| 108 | SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports, 2016, 16, 92. | 1.7 | 83 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1407-1417. | 1.5 | 74 |
| 110 | Time for reconciliation between cardiologists and diabetologists. Nature Reviews Cardiology, 2016, 13, 509-510. | 6.1 | 6 |
| 111 | Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. Diabetes and Metabolism, 2016, 42, 224-233. | 1.4 | 60 |
| 112 | Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes and Metabolism, 2016, 42, 71-76. | 1.4 | 49 |
| 113 | Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Review of Clinical Pharmacology, 2016, 9, 385-399. | 1.3 | 20 |
| 114 | Investigational insulin secretagogues for type 2 diabetes. Expert Opinion on Investigational Drugs, 2016, 25, 405-422. | 1.9 | 37 |
| 115 | Will delayed release metformin provide better management of diabetes type 2?. Expert Opinion on Pharmacotherapy, 2016, 17, 627-630. | 0.9 | 12 |
| 116 | A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency. Nutrients, 2015, 7, 5413-5422. | 1.7 | 19 |
| 117 | Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. Diabetes Care, 2015, 38, 1161-1172. | 4.3 | 170 |
| 118 | Inflammatory markers and cardiometabolic diseases. Acta Clinica Belgica, 2015, 70, 193-199. | 0.5 | 61 |
| 119 | Insulinosensibilisateurs (metformine/glitazones) : niveau de preuve et controverse. Medecine Des Maladies Metaboliques, 2015, 9, 759-767. | 0.1 | 0 |
| 120 | A review of gliptins for 2014. Expert Opinion on Pharmacotherapy, 2015, 16, 43-62. | 0.9 | 88 |
| 121 | Effect of brivaracetam on CYP3A activity, measured by oral midazolam. Journal of Clinical Pharmacology, 2015, 55, 543-548. | 1.0 | 20 |
| 122 | Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety, 2015, 14, 505-524. | 1.0 | 92 |
| 123 | Once-weekly DPP-4 inhibitors: do they meet an unmet need?. Lancet Diabetes and Endocrinology, the, 2015, 3, 162-164. | 5.5 | 13 |
| 124 | A new paradigm for treating obesity and diabetes mellitus. Nature Reviews Endocrinology, 2015, 11, 196-198. | 4.3 | 16 |
| 125 | Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium. BMC Family Practice, 2015, 16, 13. | 2.9 | 18 |
| 126 | Obese subjects involvement in a population-based survey: the use of information and communication technologies (ICT) to avoid stigmatization. Quality of Life Research, 2015, 24, 1131-1135. | 1.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. <i>Diabetes and Metabolism</i> , 2015, 41, 216-222. | 1.4 | 12 |
| 128 | Authorâ€™s Reply to De Ponti et al.: âœPharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitusâœ. <i>Clinical Pharmacokinetics</i> , 2015, 54, 449-451. | 1.6 | 0 |
| 129 | Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1005-1020. | 1.5 | 8 |
| 130 | Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. <i>Diabetes and Metabolism</i> , 2015, 41, 183-194. | 1.4 | 121 |
| 131 | Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , 2015, 54, 691-708. | 1.6 | 141 |
| 132 | Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment. <i>Evidence-Based Medicine</i> , 2015, 20, 115-115. | 0.6 | 2 |
| 133 | SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1879-1904. | 1.0 | 58 |
| 134 | Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 667-669. | 5.5 | 8 |
| 135 | Pharmacodynamics, Efficacy and Safety of SodiumâœGlucose Co-Transporter Typeâœ (SGLT2) Inhibitors for the Treatment of Typeâœ Diabetes Mellitus. <i>Drugs</i> , 2015, 75, 33-59. | 4.9 | 417 |
| 136 | Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Typeâœ Diabetes. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1-21. | 1.6 | 86 |
| 137 | Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 283-307. | 1.9 | 211 |
| 138 | Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes. <i>Annals of Translational Medicine</i> , 2015, 3, S36. | 0.7 | 2 |
| 139 | Factors associated with clinical inertia: an integrative review. <i>Advances in Medical Education and Practice</i> , 2014, 5, 141. | 0.7 | 84 |
| 140 | Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. <i>Diabetes and Metabolism</i> , 2014, 40, S4-S11. | 1.4 | 90 |
| 141 | Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?. <i>Diabetes and Metabolism</i> , 2014, 40, S1-S3. | 1.4 | 5 |
| 142 | Alogliptin: Concern About Hepatotoxicity?. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1057-1059. | 1.6 | 13 |
| 143 | Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 911-922. | 5.5 | 155 |
| 144 | Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. <i>Diabetes and Metabolism</i> , 2014, 40, 176-185. | 1.4 | 61 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2014, 53, 295-304. | 1.6 | 60 |
| 146 | Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter-2 Inhibitor. <i>Clinical Pharmacokinetics</i> , 2014, 53, 213-225. | 1.6 | 154 |
| 147 | Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 105, 141-150. | 1.1 | 1,420 |
| 148 | Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type-2 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2014, 53, 773-785. | 1.6 | 42 |
| 149 | Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 647-663. | 1.5 | 53 |
| 150 | Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. <i>Biochemical Pharmacology</i> , 2014, 92, 131-141. | 2.0 | 134 |
| 151 | Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 839-857. | 1.5 | 52 |
| 152 | Which incretin-based therapy for type 2 diabetes?. <i>Lancet, The</i> , 2014, 384, 1325-1327. | 6.3 | 10 |
| 153 | Personalising metformin therapy: a clinician's perspective. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 442-444. | 5.5 | 9 |
| 154 | SGLT2 versus DPP4 inhibitors for type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2013, 1, 168-170. | 5.5 | 23 |
| 155 | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087. | 1.0 | 1,758 |
| 156 | Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. <i>Diabetologia</i> , 2013, 56, 2487-2497. | 2.9 | 202 |
| 157 | Efficacy and safety of Jentaduetto® (linagliptin plus metformin). <i>Expert Opinion on Drug Safety</i> , 2013, 12, 275-289. | 1.0 | 6 |
| 158 | Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 370-375. | 1.2 | 7 |
| 159 | GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?. <i>Annales D'Endocrinologie</i> , 2013, 74, 515-522. | 0.6 | 20 |
| 160 | Cardiovascular effects of gliptins. <i>Nature Reviews Cardiology</i> , 2013, 10, 73-84. | 6.1 | 154 |
| 161 | Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2013, 39, 179-190. | 1.4 | 137 |
| 162 | Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 545-557. | 1.0 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 529-550. | 1.5 | 77 |
| 164 | Issues in performing a network meta-analysis. Statistical Methods in Medical Research, 2013, 22, 169-189. | 0.7 | 62 |
| 165 | Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine, 2013, 125, 7-20. | 0.9 | 71 |
| 166 | Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. Journal of Lipid Research, 2013, 54, 2998-3008. | 2.0 | 126 |
| 167 | Critical assessment of diabetic xerosis. Expert Opinion on Medical Diagnostics, 2013, 7, 201-207. | 1.6 | 12 |
| 168 | Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 363-377. | 1.5 | 9 |
| 169 | The skin landscape in diabetes mellitus. Focus on dermocosmetic management. Clinical, Cosmetic and Investigational Dermatology, 2013, 6, 127. | 0.8 | 26 |
| 170 | Gliptin versus a sulphonylurea as add-on to metformin. Lancet, The, 2012, 380, 450-452. | 6.3 | 24 |
| 171 | Metformin + saxagliptin for type 2 diabetes. Expert Opinion on Pharmacotherapy, 2012, 13, 139-146. | 0.9 | 16 |
| 172 | Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. European Neuropsychopharmacology, 2012, 22, 17-26. | 0.3 | 37 |
| 173 | Outcomes and lessons from the PROactive study. Diabetes Research and Clinical Practice, 2012, 98, 175-186. | 1.1 | 36 |
| 174 | MÃ©dicaments de lâ€™obÃ©sitÃ© et risque cardiovasculaire. Medecine Des Maladies Metaboliques, 2012, 6, 31-37. | 0.1 | 0 |
| 175 | Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 745-758. | 1.5 | 10 |
| 176 | Saxagliptin plus metformin combination therapy. Expert Review of Endocrinology and Metabolism, 2012, 7, 151-164. | 1.2 | 2 |
| 177 | Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 383-394. | 1.5 | 11 |
| 178 | Haemodynamic changes during a squat test, pulsatile stress and indices of cardiovascular autonomic neuropathy in patients with long-duration type 1 diabetes. Diabetes and Metabolism, 2012, 38, 54-62. | 1.4 | 6 |
| 179 | DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes and Metabolism, 2012, 38, 89-101. | 1.4 | 157 |
| 180 | Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes. European Journal of Internal Medicine, 2012, 23, 126-131. | 1.0 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors. <i>Diabetologia</i> , 2012, 55, 2848-2849. | 2.9 | 7 |
| 182 | A review of gliptins in 2011. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 81-99. | 0.9 | 99 |
| 183 | Squatting test: a dynamic postural manoeuvre to study baroreflex sensitivity. <i>Clinical Autonomic Research</i> , 2012, 22, 35-41. | 1.4 | 15 |
| 184 | Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1561-1576. | 1.5 | 29 |
| 185 | Le tractus digestif comme organe endocrine: une nouvelle vision de la chirurgie bariatrique. <i>Medecine Des Maladies Metaboliques</i> , 2011, 5, 155-161. | 0.1 | 2 |
| 186 | Squatting, a posture test for studying cardiovascular autonomic neuropathy in diabetes. <i>Diabetes and Metabolism</i> , 2011, 37, 489-496. | 1.4 | 15 |
| 187 | Squatting test: A posture to study and counteract cardiovascular abnormalities associated with autonomic dysfunction. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2011, 162, 3-9. | 1.4 | 15 |
| 188 | Facing up to the imperceptible perspiration. Modulatory influences by diabetic neuropathy, physical exercise and antiperspirant. <i>Skin Research and Technology</i> , 2011, 17, 487-493. | 0.8 | 16 |
| 189 | Hypocortisolism induces chronic respiratory failure. <i>Respiratory Medicine CME</i> , 2011, 4, 107-108. | 0.1 | 3 |
| 190 | Sibutramine on Cardiovascular Outcome. <i>Diabetes Care</i> , 2011, 34, S114-S119. | 4.3 | 43 |
| 191 | Cytochrome P450-mediated cardiovascular drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1065-1082. | 1.5 | 26 |
| 192 | Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 540-549. | 1.7 | 154 |
| 193 | Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 648-658. | 2.2 | 250 |
| 194 | Pulsatile Stress in Middle-Aged Patients With Type 1 or Type 2 Diabetes Compared With Nondiabetic Control Subjects. <i>Diabetes Care</i> , 2010, 33, 2424-2429. | 4.3 | 5 |
| 195 | Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490. | 13.9 | 588 |
| 196 | Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476. | 13.9 | 430 |
| 197 | L'hyperglycémie provoquée par voie orale (HGPO) revisitée. <i>Medecine Des Maladies Metaboliques</i> , 2010, 4, 569-574. | 0.1 | 3 |
| 198 | Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1265-1276. | 1.5 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Dipeptidylpeptidase-4 Inhibitors (Gliptins). <i>Clinical Pharmacokinetics</i> , 2010, 49, 573-588. | 1.6 | 124 |
| 200 | Controversy about the Cardiovascular Safety of Sibutramine. <i>Drug Safety</i> , 2010, 33, 615-618. | 1.4 | 4 |
| 201 | Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2163-2171. | 1.8 | 53 |
| 202 | Addition of incretin therapy to metformin in type 2 diabetes. <i>Lancet, The</i> , 2010, 375, 1410-1412. | 6.3 | 36 |
| 203 | Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. <i>Diabetes and Metabolism</i> , 2010, 36, 409-413. | 1.4 | 22 |
| 204 | Central nervous system: a conductor orchestrating metabolic regulations harmed by both hyperglycaemia and hypoglycaemia. <i>Diabetes and Metabolism</i> , 2010, 36, S31-S38. | 1.4 | 46 |
| 205 | Cardiovascular Risk-Benefit Profile of Sibutramine. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 321-334. | 1.0 | 71 |
| 206 | Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2009, 25, 442-451. | 1.7 | 25 |
| 207 | Sujets Â« mÃ©taboliquement sains Â», bien qu'obÃ©ses. PremiÃ¨re partie: diagnostic, physiopathologie et prÃ©valence. <i>Obesite</i> , 2009, 4, 56-65. | 0.1 | 3 |
| 208 | Sujets Â« mÃ©taboliquement sains Â», bien qu'obÃ©ses. DeuxiÃ¨me partie : pronostic et prise en charge. <i>Obesite</i> , 2009, 4, 134-141. | 0.1 | 1 |
| 209 | Rosiglitazone: to be or not to be?. <i>Diabetologia</i> , 2009, 52, 1448-1450. | 2.9 | 1 |
| 210 | Long-term glycaemic control with metformin+sulphonylurea+pioglitazone triple therapy in PROactive (PROactive 17). <i>Diabetic Medicine</i> , 2009, 26, 1033-1039. | 1.2 | 41 |
| 211 | Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 103-116. | 2.2 | 50 |
| 212 | Bariatric surgery in patients with Type 2 diabetes: benefits, risks, indications and perspectives. <i>Diabetes and Metabolism</i> , 2009, 35, 537-543. | 1.4 | 21 |
| 213 | Voglibose for prevention of type 2 diabetes mellitus. <i>Lancet, The</i> , 2009, 373, 1579-1580. | 6.3 | 14 |
| 214 | The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes. <i>Current Protein and Peptide Science</i> , 2009, 10, 56-74. | 0.7 | 22 |
| 215 | Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa. <i>Clinical Nephrology</i> , 2009, 71, 482-491. | 0.4 | 21 |
| 216 | Metabolically obese normal-weight subjects. Part two: prognosis and management. <i>Obesite</i> , 2008, 3, 280-285. | 0.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2008, 10, 342-348. | 1.1 | 168 |
| 218 | Abdominal adiposity: Early intervention and therapeutic options. <i>Clinical Cornerstone</i> , 2008, 9, S20-S27. | 1.0 | 4 |
| 219 | Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. <i>Schizophrenia Research</i> , 2008, 101, 295-303. | 1.1 | 217 |
| 220 | A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , 2008, 106, 308-314. | 1.1 | 40 |
| 221 | Exenatide once weekly in type 2 diabetes. <i>Lancet</i> , The, 2008, 372, 1197-1198. | 6.3 | 23 |
| 222 | Traitements neuroleptiques et troubles mÃ©taboliques. <i>Medecine Des Maladies Metaboliques</i> , 2008, 2, 593-599. | 0.1 | 4 |
| 223 | The future of obesity: new drugs versus lifestyle interventions. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 263-267. | 1.9 | 39 |
| 224 | Squatting Amplifies Pulse Pressure Increase With Disease Duration in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 322-324. | 4.3 | 11 |
| 225 | Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. <i>European Heart Journal</i> , 2008, 29, 1761-1771. | 1.0 | 137 |
| 226 | Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients. <i>Diabetes Care</i> , 2008, 31, S229-S240. | 4.3 | 186 |
| 227 | NEW THERAPEUTIC APPROACHES IN TYPE 2 DIABETES. <i>Acta Clinica Belgica</i> , 2008, 63, 402-407. | 0.5 | 22 |
| 228 | MEDICATIONS IN THE KIDNEY. <i>Acta Clinica Belgica</i> , 2008, 63, 76-80. | 0.5 | 14 |
| 229 | Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 260-261. | 2.9 | 6 |
| 230 | Inhibitors of cannabinoid receptors and glucose metabolism. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 505-511. | 1.3 | 13 |
| 231 | Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. <i>Journal of Hypertension</i> , 2008, 26, 357-367. | 0.3 | 67 |
| 232 | Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. <i>Acta Cardiologica</i> , 2008, 63, 235-248. | 0.3 | 7 |
| 233 | Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 472-479. | 1.1 | 88 |
| 234 | Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1319-1327. | 1.1 | 67 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. <i>European Heart Journal</i> , 2007, 28, 1401-1402. | 1.0 | 7 |
| 236 | A Case Series: Evaluation of the Metabolic Safety of Aripiprazole. <i>Schizophrenia Bulletin</i> , 2007, 33, 823-830. | 2.3 | 68 |
| 237 | Efficacy of Indapamide SR Compared With Enalapril in Elderly Hypertensive Patients With Type 2 Diabetes. <i>American Journal of Hypertension</i> , 2007, 20, 90-97. | 1.0 | 22 |
| 238 | Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?. <i>Diabetes and Metabolism</i> , 2007, 33, 3-12. | 1.4 | 43 |
| 239 | Abnormal glucose metabolism in patients treated with antipsychotics. <i>Diabetes and Metabolism</i> , 2007, 33, 169-175. | 1.4 | 146 |
| 240 | Rimonabant in obese patients with type 2 diabetes – Authors' reply. <i>Lancet, The</i> , 2007, 369, 554-555. | 6.3 | 1 |
| 241 | Lipodystrophy Reactions to Insulin. <i>American Journal of Clinical Dermatology</i> , 2007, 8, 21-28. | 3.3 | 82 |
| 242 | The safety of obesity drugs – correspondence. <i>Expert Opinion on Drug Safety</i> , 2007, 6, 475-476. | 1.0 | 0 |
| 243 | Pharmacokinetic Interactions with Thiazolidinediones. <i>Clinical Pharmacokinetics</i> , 2007, 46, 1-12. | 1.6 | 53 |
| 244 | Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide. <i>Clinical Pharmacokinetics</i> , 2007, 46, 93-108. | 1.6 | 64 |
| 245 | Cannabinoid-1 receptor antagonists in type-2 diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 535-553. | 2.2 | 21 |
| 246 | Nutritional Counseling for Overweight Patients and Patients with Metabolic Syndrome. , 2007, , 201-211. | | 1 |
| 247 | Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2007, 22, 43-9. | 0.9 | 43 |
| 248 | Metformin Extended Release. <i>American Journal of Drug Delivery</i> , 2006, 4, 187-188. | 0.6 | 0 |
| 249 | Does the metabolic syndrome help to select patients requiring high statin dose?. <i>Lancet, The</i> , 2006, 368, 893-894. | 6.3 | 6 |
| 250 | Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. <i>Lancet, The</i> , 2006, 368, 1660-1672. | 6.3 | 722 |
| 251 | Oral glucose tolerance tests in treated patients with schizophrenia.. <i>European Psychiatry</i> , 2006, 21, 224-226. | 0.1 | 31 |
| 252 | Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. <i>Schizophrenia Research</i> , 2006, 83, 87-93. | 1.1 | 274 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Aspirin and clopidogrel resistance in patients with diabetes mellitus. <i>European Heart Journal</i> , 2006, 27, 2900-2900. | 1.0 | 15 |
| 254 | Reversibility of Antipsychotic Treatment-Related Diabetes in Patients With Schizophrenia: A case series of switching to aripiprazole. <i>Diabetes Care</i> , 2006, 29, 2329-2330. | 4.3 | 24 |
| 255 | Insulin detemir in the treatment of type 1 and type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2006, 2, 277-283. | 1.0 | 16 |
| 256 | Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1493-1500. | 1.1 | 79 |
| 257 | Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1889-1896. | 1.1 | 63 |
| 258 | Diabetes, Obesity, and Metabolic Syndrome. <i>Nutrition and Disease Prevention</i> , 2006, , 1-30. | 0.1 | 2 |
| 259 | Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. <i>Lancet</i> , The, 2005, 365, 1389-1397. | 6.3 | 1,447 |
| 260 | Effect of rimonabant on weight reduction and cardiovascular risk. <i>Lancet</i> , The, 2005, 366, 369-370. | 6.3 | 17 |
| 261 | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet</i> , The, 2005, 366, 1279-1289. | 6.3 | 3,840 |
| 262 | Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?. <i>Diabetes and Metabolism</i> , 2005, 31, 5S27-5S34. | 1.4 | 116 |
| 263 | Drug Interactions of Clinical Importance with Antihyperglycaemic Agents. <i>Drug Safety</i> , 2005, 28, 601-631. | 1.4 | 121 |
| 264 | Drug-eluting stents: meta-analysis in diabetic patients. <i>European Heart Journal</i> , 2004, 25, 2167-2168. | 1.0 | 65 |
| 265 | Diabetes Is Still a Risk Factor for Restenosis After Drug-Eluting Stent in Coronary Arteries. <i>Diabetes Care</i> , 2004, 27, 1840-1841. | 4.3 | 41 |
| 266 | Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 178-188. | 1.7 | 76 |
| 267 | Acanthosis Nigricans Associated with Insulin Resistance. <i>American Journal of Clinical Dermatology</i> , 2004, 5, 199-203. | 3.3 | 129 |
| 268 | Pathophysiology of insulin secretion. <i>Annales D'Endocrinologie</i> , 2004, 65, 29-36. | 0.6 | 30 |
| 269 | Combined Thiazolidinedione-Insulin Therapy. <i>Drug Safety</i> , 2004, 27, 841-856. | 1.4 | 63 |
| 270 | Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System. <i>Drugs</i> , 2004, 64, 2537-2565. | 4.9 | 239 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Tolerability Profile of Metformin/Glibenclamide Combination Tablets (Glucoavance?). Drug Safety, 2004, 27, 1205-1216. | 1.4 | 15 |
| 272 | Le syndrome métabolique: comparaison des paramètres biologiques dans différentes définitions. Immuno-Analyse Et Biologie Spécialisée, 2004, 19, 188-194. | 0.0 | 4 |
| 273 | Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes and Metabolism, 2004, 30, 487-496. | 1.4 | 238 |
| 274 | Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes and Metabolism, 2004, 30, 498-505. | 1.4 | 155 |
| 275 | VALUE: analysis of results. Lancet, The, 2004, 364, 932-933. | 6.3 | 17 |
| 276 | Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes. Journal of Hypertension, 2004, 22, 1613-1622. | 0.3 | 127 |
| 277 | Integrated Approach to Treatment and Prevention. , 2004, , 449-463. | | 2 |
| 278 | Is There a Role for α -Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?. Drugs, 2003, 63, 933-951. | 4.9 | 197 |
| 279 | Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. Drugs, 2003, 63, 1165-1184. | 4.9 | 76 |
| 280 | L'hyperglycémie provoquée par voie orale. Étude de la sécrétion, de la clairance et de l'action de l'insuline, et du contrôle par les hormones de la contre-régulation. Immuno-Analyse Et Biologie Spécialisée, 2003, 18, 185-190. | 0.0 | 3 |
| 281 | Preventing, Delaying, or Masking Type 2 Diabetes With Metformin in the Diabetes Prevention Program?. Diabetes Care, 2003, 26, 2701-2701. | 4.3 | 9 |
| 282 | PATHOPHYSIOLOGY OF TYPE 2 DIABETES. Acta Clinica Belgica, 2003, 58, 335-341. | 0.5 | 182 |
| 283 | Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes. Hypertension, 2003, 41, 1063-1071. | 1.3 | 142 |
| 284 | PREVENTION OF CARDIOVASCULAR DISEASE : PLEA FOR A RATIONALE USE OF DIET AND LIPID-LOWERING DRUGS. Acta Clinica Belgica, 2003, 58, 149-151. | 0.5 | 0 |
| 285 | TREATMENT OF TYPE 2 DIABETES. Acta Clinica Belgica, 2003, 58, 318-324. | 0.5 | 18 |
| 286 | NONALCOHOLIC STEATOHEPATITIS AND INSULIN RESISTANCE : INTERFACE BETWEEN GASTROENTEROLOGISTS AND ENDOCRINOLOGISTS. Acta Clinica Belgica, 2003, 58, 106-116. | 0.5 | 15 |
| 287 | Potential Pharmacokinetics Interference Between α -Glucosidase Inhibitors and Other Oral Antidiabetic Agents. Diabetes Care, 2002, 25, 247-248. | 4.3 | 10 |
| 288 | Relation between Disease Phenotype and HLA-DQ Genotype in Diabetic Patients Diagnosed in Early Adulthood. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2597-2605. | 1.8 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Obesity and liver disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2002, 16, 703-716. | 2.2 | 110 |
| 290 | Acarbose for type 2 diabetes prevention. Lancet, The, 2002, 360, 1516. | 6.3 | 7 |
| 291 | Hepatic Insulin Resistance in Obese Non-Diabetic Subjects and in Type 2 Diabetic Patients. Obesity, 2002, 10, 129-134. | 4.0 | 30 |
| 292 | Are all glitazones the same?. Diabetes/Metabolism Research and Reviews, 2002, 18 Suppl 2, S1-4. | 1.7 | 5 |
| 293 | New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes and Metabolism, 2002, 28, 437-45. | 1.4 | 36 |
| 294 | Hepatotoxicity with Thiazolidinediones. Drug Safety, 2001, 24, 873-888. | 1.4 | 121 |
| 295 | Thiazolidinediones and liver toxicity. Diabetes and Metabolism, 2001, 27, 305-13. | 1.4 | 112 |
| 296 | From Obesity to Diabetes: Why, When and Who?. Acta Clinica Belgica, 2000, 55, 9-15. | 0.5 | 39 |
| 297 | Antiobesity pharmacotherapy in the management of Type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2000, 16, 114-124. | 1.7 | 25 |
| 298 | Assessment of postprandial hepatic glycogen synthesis from uridine diphosphoglucose kinetics in obese and lean non-diabetic subjects. International Journal of Obesity, 2000, 24, 1297-1302. | 1.6 | 4 |
| 299 | No Increased Insulin Sensitivity after a Single Intravenous Administration of a Recombinant Human Tumor Necrosis Factor Receptor: Fc Fusion Protein in Obese Insulin-Resistant Patients*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1316-1319. | 1.8 | 166 |
| 300 | Exploration et suivi biologique d'un patient obèse. Immuno-Analyse Et Biologie Specialisee, 2000, 15, 250-254. | 0.0 | 2 |
| 301 | Treatment of diabetes in patients with severe obesity. Biomedicine and Pharmacotherapy, 2000, 54, 74-79. | 2.5 | 20 |
| 302 | Parallel Reversibility of Biological Markers of the Metabolic Syndrome and Liver Steatosis after Gastroplasty-Induced Weight Loss in Severe Obesity. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4293-4293. | 1.8 | 31 |
| 303 | Pharmacological treatment of obesity: present status. International Journal of Obesity, 1999, 23, S47-S53. | 1.6 | 52 |
| 304 | CAPP trial. Lancet, The, 1999, 353, 1793-1794. | 6.3 | 5 |
| 305 | Non-alcoholic steatohepatitis. Lancet, The, 1999, 354, 1298-1299. | 6.3 | 7 |
| 306 | Severe / Extreme Obesity: A Medical Disease Requiring A Surgical Treatment?. Acta Clinica Belgica, 1999, 54, 154-161. | 0.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. International Journal of Obesity, 1998, 22, 222-226. | 1.6 | 432 |
| 308 | The postprandial state and risk of cardiovascular disease. Diabetic Medicine, 1998, 15, S63-S68. | 1.2 | 62 |
| 309 | Oral Antidiabetic Agents. Drugs, 1998, 55, 225-236. | 4.9 | 114 |
| 310 | The Roles of Time of Day and Sleep Quality in Modulating Glucose Regulation: Clinical Implications. Hormone Research in Paediatrics, 1998, 49, 191-201. | 0.8 | 53 |
| 311 | Influence of the Aâ†'G (-3826) uncoupling protein-1 gene (UCP1) variant on the dynamics of body weight before and after gastroplasty in morbidly obese subjects. International Journal of Obesity, 1998, 22, 1244-1245. | 1.6 | 7 |
| 312 | The postprandial state and risk of cardiovascular disease. Diabetic Medicine, 1998, 15, S63-S68. | 1.2 | 3 |
| 313 | The postprandial state and risk of cardiovascular disease. Diabetic Medicine, 1998, 15, S63-S68. | 1.2 | 92 |
| 314 | Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Drugs, 1997, 54, 355-368. | 4.9 | 123 |
| 315 | Non-insulin-dependent diabetes mellitus in the elderly. Bailliere's Clinical Endocrinology and Metabolism, 1997, 11, 389-406. | 1.0 | 15 |
| 316 | Clinical Pharmacokinetics of Metformin. Clinical Pharmacokinetics, 1996, 30, 359-371. | 1.6 | 512 |
| 317 | Usefulness of Fluoxetine in Obese Non-Insulin-Dependent Diabetics: A Multicenter Study. Obesity, 1996, 4, 391-396. | 4.0 | 46 |
| 318 | Insulin Resistance Syndrome and Atherosclerotic Cardiovascular Disease. Acta Clinica Belgica, 1996, 51, 65-69. | 0.5 | 8 |
| 319 | Lessons From the Discovery of Leptin: is Obesity an Endocrine Disease?. Acta Clinica Belgica, 1996, 51, 371-376. | 0.5 | 4 |
| 320 | Treatment with insulin infusion pumps and ketoacidotic episodes: From physiology to troubleshooting. Diabetes/metabolism Reviews, 1995, 11, 161-177. | 0.4 | 8 |
| 321 | Effects of metformin in obese patients with impaired glucose tolerance. Diabetes/metabolism Reviews, 1995, 11, S69-S80. | 0.4 | 14 |
| 322 | Short Administration of Metformin Improves Insulin Sensitivity in Android Obese Subjects with Impaired Glucose Tolerance. Diabetic Medicine, 1995, 12, 985-989. | 1.2 | 41 |
| 323 | Antihyperglycaemic Agents Drug Interactions of Clinical Importance. Drug Safety, 1995, 12, 32-45. | 1.4 | 45 |
| 324 | How to measure insulin clearance. Diabetes/metabolism Reviews, 1994, 10, 119-150. | 0.4 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | How to measure insulin action <i>in vivo</i>. <i>Diabetes/metabolism Reviews</i> , 1994, 10, 151-188. | 0.4 | 79 |
| 326 | 10 Therapy for obesityâ€™today and tomorrow. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1994, 8, 705-727. | 1.0 | 12 |
| 327 | Contributors to Volume 20. <i>Methods in Neurosciences</i> , 1994, 20, ix-xiii. | 0.5 | 0 |
| 328 | Combination of Oral Antidiabetic Drugs and Insulin in the Treatment of Non-Insulin-Dependent Diabetes. <i>Acta Clinica Belgica</i> , 1993, 48, 259-268. | 0.5 | 15 |
| 329 | Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism. <i>Fertility and Sterility</i> , 1993, 59, 797-802. | 0.5 | 19 |
| 330 | Management of Non-Insulin-Dependent Diabetes Mellitus. <i>Drugs</i> , 1992, 44, 29-38. | 4.9 | 18 |
| 331 | Devices for the Treatment of Diabetes: Today. <i>Artificial Organs</i> , 1992, 16, 163-166. | 1.0 | 2 |
| 332 | Pulsatile Insulin Delivery has Greater Metabolic Effects than Continuous Hormone Administration in Man: Importance of Pulse Frequency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 607-615. | 1.8 | 100 |
| 333 | Improvement of Insulin-Induced Glucose Disposal in Obese Patients With NIDDM After 1-Wk Treatment With d-Fenfluramine. <i>Diabetes Care</i> , 1991, 14, 325-332. | 4.3 | 75 |
| 334 | Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: A one-year randomized, prospective, comparative trial. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 163, 378-381. | 0.7 | 14 |
| 335 | Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in Type 1 (insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1989, 32, 801-9. | 2.9 | 10 |
| 336 | Impaired insulin-induced erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1988, 31, 910-5. | 2.9 | 66 |
| 337 | The addition of glipizide to insulin therapy in Type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. <i>European Journal of Endocrinology</i> , 1987, 116, 364-372. | 1.9 | 27 |
| 338 | Primary role of glucagon release in the effect of β^2 -endorphin on glucose homeostasis in normal man. <i>European Journal of Endocrinology</i> , 1987, 115, 161-169. | 1.9 | 31 |
| 339 | Insulin Oscillations per se Do Not Affect Glucose Turnover Parameters in Normal Man*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 63, 520-525. | 1.8 | 18 |
| 340 | Blood collection while using a continuous glucose analyzer without insertion of an additional venous catheter. <i>Diabetologia</i> , 1983, 25, 120-2. | 2.9 | 2 |
| 341 | A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. <i>Diabetologia</i> , 1983, 24, 319-25. | 2.9 | 12 |
| 342 | Pharmacological Prevention of Type 2 Diabetes. , 0, , 449-474. | | 1 |